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Proteinase activated receptor 2 (PAR2) modulation of airway smooth muscle function 
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Goodyear4, J.C. Lockhart1, G.J. Litherland1 
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Biomedical and Environmental Health Research, School of Health & Life Sciences, 
University of the West of Scotland, Paisley, Scotland. 2Queens University Belfast. 3Dundalk 
Institute of Technology. 4Institute of Infection, Immunity & Inflammation, University of 
Glasgow.  
Chronic obstructive pulmonary disease (COPD) is a progressive lung condition characterised 
by airflow obstruction and irreversible lung damage. Hyperactivity and growth of airway 
smooth muscle (ASM) limit airflow and are key features of COPD. Proteinase activated 
receptor-2 (PAR2) is a key modulator of inflammatory responses in respiratory disease, such 
as asthma and promotes ASM relaxation. However, the precise role of the receptor in ASM in 
conditions such as COPD is not well understood (1). The aim of this study was to establish an 
ex vivo murine airway myograph assay for investigation of functional PAR2 responses to 
challenges relevant in COPD pathology.  
To achieve this, murine trachea and bronchi tissue was either mounted on a wire myograph for 
dynamic tension recording or processed for immunohistochemical localisation of PAR2 
expression.  
PAR2 was present on both murine airway and lung tissue. Stimulation of PAR2 with trypsin 
(10 U ml-1) or activating peptide was observed to induce relaxation responses in ASM tension.  
Taken together this data verifies that PAR2 is present and functional in murine airways, and ex 
vivo modulation alters ASM tone. Ongoing experiments will investigate the effect of disease-
relevant insults on this modulation in wild type and PAR2-deficient airways.  
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